<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Females and lung cancer</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Females and lung cancer</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Females and lung cancer</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Elizabeth H Baldini, MD, MPH, FASTRO</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter J Barnes, DM, DSc, FRCP, FRS</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Rogerio C Lilenbaum, MD, FACP</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sadhna R Vora, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 27, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>The epidemic of lung cancer in females is reviewed here, focusing on epidemiologic issues, risk factors, outcome, and prevention. General issues related to lung cancer risk and its clinical presentation are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/4641.html" rel="external">"Clinical manifestations of lung cancer"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">EPIDEMIOLOGY</span><span class="headingEndMark"> — </span>Worldwide, lung cancer is among the most common cancers and cancer death in females. In the United States, lung cancer is the leading cancer killer of females, having surpassed breast cancer in 1987  (<a class="graphic graphic_table graphicRef143118" href="/z/d/graphic/143118.html" rel="external">table 1</a>). Approximately 40 percent more females in the United States are expected to die annually from lung cancer compared with breast cancer [<a href="#rid1">1</a>].</p><p>The age-adjusted lung cancer death rate has risen in parallel to the smoking rate among females, with the increase in lung cancer deaths following the increase in smoking incidence by approximately 20 years. This separation reflects the latency period between smoking and death from lung cancer. Specifically, the smoking rate for females rose dramatically in the United States from 1930 to 1960, and this was followed by a rapidly increasing lung cancer death rate that began in 1960  (<a class="graphic graphic_figure graphicRef143119" href="/z/d/graphic/143119.html" rel="external">figure 1</a>) [<a href="#rid1">1-6</a>]. The lung cancer death rate in females reached a plateau and has now started to decline, with a reported decrease of 1.1 percent per year since 2006 to 2007 [<a href="#rid1">1,6</a>]. The same trend has been documented in many European countries [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H3"><span class="h2">Comparison of males and females</span><span class="headingEndMark"> — </span>Lung cancer mortality has been and continues to be more common in males than females [<a href="#rid8">8</a>]. However, the magnitude of this difference continues to decline [<a href="#rid9">9,10</a>].</p><p>The age-adjusted lung cancer incidence has historically been higher in males than females. However, the magnitude of this difference has decreased [<a href="#rid1">1,2,4,10,11</a>]. Moreover, given that the incidence of lung cancer has declined more steeply in young males than in young females over the past two decades, the incidence of lung cancer in non-Hispanic White individuals in the 30 to 49 year old age group is higher in females than in males, according to cancer registry data from 1995 through 2014 [<a href="#rid12">12</a>]. This reversal in trends is not accounted for by sex difference in smoking behaviors.</p><p>Among nonsmokers, the age-adjusted incidence rate of lung cancer is higher for females (14.4 to 20.8 per 100,000 person-years) than males (4.8 to 13.7 per 100,000 person-years) according to a pooled analysis of six prospective cohort studies [<a href="#rid13">13</a>]. Furthermore, in the United States, approximately 19 percent of lung cancer in females arise in never smokers compared with only 9 percent for males. However, there is no clear evidence that lung cancer in never smoking young females is increasing [<a href="#rid14">14</a>]. (See  <a class="medical medical_review" href="/z/d/html/4600.html" rel="external">"Lung cancer in never smokers"</a>.)</p><p class="headingAnchor" id="H4"><span class="h1">RISK FACTORS</span><span class="headingEndMark"> — </span>Given that smoking is the most important risk factor for the development of lung cancer in both females and males, the question arises whether there is a sex-related difference in the magnitude of the relationship between smoking and lung cancer. An additional question is whether endocrine factors affect the risk of lung cancer.</p><p class="headingAnchor" id="H5"><span class="h2">Tobacco exposure</span><span class="headingEndMark"> — </span>Cigarette smoking is the main culprit for the lung cancer epidemic in females, with estimates suggesting up to 80 percent of lung cancer cases in females are related to smoking [<a href="#rid15">15,16</a>]. Females started smoking in significant numbers during and following World War II. Although smoking rates have declined since their peak in the 1960s, the current prevalence of smoking among females in the United States is still too high with an estimated 16.5 percent of females smoking in 2011  (<a class="graphic graphic_figure graphicRef65613" href="/z/d/graphic/65613.html" rel="external">figure 2</a>) [<a href="#rid17">17</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.)</p><p>Reported relative risks (RR) for the development of lung cancer in female smokers compared with female nonsmokers vary greatly. RRs from reports range from 7.8 to 37.5 [<a href="#rid18">18-23</a>]. Furthermore, the magnitude of the risk increases with the duration of smoking and with the total exposure to cigarettes [<a href="#rid16">16,22,24</a>]. The risk in females who are former smokers remains significantly elevated compared with never smokers [<a href="#rid23">23</a>].</p><p>Passive smoking may also be associated with increased risk of lung cancer in never smokers, although the increased risk appears to be predominantly in females with prolonged exposure as an adult [<a href="#rid23">23</a>]. (See  <a class="medical medical_review" href="/z/d/html/4600.html" rel="external">"Lung cancer in never smokers", section on 'Secondhand smoke'</a> and  <a class="medical medical_review" href="/z/d/html/6919.html" rel="external">"Secondhand smoke exposure: Effects in adults", section on 'Lung cancer'</a>.)</p><p>Evidence is mixed but suggests that female smokers may have a higher RR of developing lung cancer than male smokers [<a href="#rid25">25-29</a>]. For example, in a large cohort study of almost 600,000 participants, approximately 6500 of whom developed lung cancer over the course of follow-up, female current smokers experienced a statistically significant increase in lung cancer risk compared with male smokers (hazard ratios [HRs] relative to nonsmokers were 1.64 for female smokers and 1.43 for male smokers) [<a href="#rid29">29</a>].</p><p>Lung cancer is not the only smoking-related tragedy in females. The World Health Organization (WHO) showed that at least 25 percent of female smokers die from a smoking-related disease [<a href="#rid30">30</a>]. In absolute numbers, approximately 300,000 females in developed countries died of smoking-related diseases in 1985. The most important smoking-related causes of death were cardiovascular disease (41 percent), lung cancer (21 percent), and chronic obstructive pulmonary disease (18 percent) [<a href="#rid30">30</a>]. Other causes include cancers of the esophagus, head and neck, and other sites as well as other respiratory diseases.</p><p>A subsequent report estimated that in 2000 there were 4.83 million deaths in the world due to smoking with an even split between industrialized and nonindustrialized. About one million of these deaths were in females, and the principal causes of death remained cardiovascular disease, lung cancer, and chronic obstructive pulmonary disease [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/1504.html" rel="external">"Cardiovascular risk of smoking and benefits of smoking cessation"</a> and  <a class="medical medical_review" href="/z/d/html/1443.html" rel="external">"Chronic obstructive pulmonary disease: Risk factors and risk reduction"</a>.)</p><p class="headingAnchor" id="H953397484"><span class="h2">Air pollution</span><span class="headingEndMark"> — </span>There is a relatively high burden of lung cancer in females in China and certain other countries in Asia and Africa, which is thought to be due to burning coal and wood for cooking in unventilated stoves [<a href="#rid32">32</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer", section on 'Air pollution and diesel exhaust'</a>.)</p><p class="headingAnchor" id="H6"><span class="h2">Radiation therapy</span><span class="headingEndMark"> — </span>Exposure to radiation is a known risk factor for subsequent development of lung cancer as well as other cancers. This was initially demonstrated in atomic bomb survivors who had an increased lung cancer incidence years following radiation exposure [<a href="#rid33">33</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer", section on 'Radiation therapy'</a>.)</p><p>Several reports have shown that survivors of Hodgkin lymphoma who have received radiation therapy (RT) to the chest have a higher risk of developing a lung cancer compared with those who did not receive RT; this risk is further increased among smokers [<a href="#rid34">34-36</a>]. (See  <a class="medical medical_review" href="/z/d/html/4764.html" rel="external">"Second malignancies after treatment of classic Hodgkin lymphoma", section on 'Lung cancer'</a>.)</p><p>Similar findings have been reported in females who have received RT for breast cancer. The incidence of lung cancer is markedly increased in females who have smoked and have received RT following mastectomy for breast cancer compared with those who never smoked and did not receive postmastectomy RT [<a href="#rid37">37</a>]. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer", section on 'Radiation therapy'</a>.)</p><p>It is unclear whether the use of modern RT techniques such as intensity modulated radiation therapy (IMRT) and/or proton therapy will affect the incidence of radiation-associated lung cancer and other radiation-associated cancers. On the one hand, the incidence may be reduced given that smaller volumes of normal tissue receive high doses with these modern conformal techniques. On the other hand, the risk of second cancers could be increased with the use of IMRT and protons due to the fact that larger volumes of normal tissue receive very low doses with such techniques [<a href="#rid38">38,39</a>].</p><p class="headingAnchor" id="H7"><span class="h2">Endocrine factors</span><span class="headingEndMark"> — </span>Large randomized studies suggest that estrogen plus progestin therapy is associated with an increased risk of lung cancer [<a href="#rid40">40-42</a>]. (See  <a class="medical medical_review" href="/z/d/html/7427.html" rel="external">"Menopausal hormone therapy: Benefits and risks"</a>.)</p><p>The most extensive data come from three prospective studies:</p><p class="bulletIndent1"><span class="glyph">●</span>In the Women's Health Initiative trial, 16,608 females were randomly assigned to estrogen-progestin therapy or placebo. There was a statistically nonsignificant trend toward an increased incidence of non-small cell lung cancer in females taking estrogen-progestin therapy when compared with placebo (0.14 versus 0.11 percent; HR 1.28, 95% CI 0.94-1.73) and an increased number of deaths from lung cancer (0.11 versus 0.06 percent; HR 1.71, 95% CI 1.16-2.52) [<a href="#rid40">40,41</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In another component of the Women's Health Initiative trial, 10,739 females who had previously undergone a hysterectomy were randomly assigned to estrogen alone or placebo [<a href="#rid43">43</a>]. In a post-hoc analysis, there was no statistically significant increase in the incidence of lung cancer after a mean follow-up of eight years (HR for incidence 1.17, 95% CI 0.81-1.69) nor was there an increase in deaths from lung cancer (HR for death 1.07, 95% CI 0.66-1.72).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>The prospective Vitamins and Lifestyle (VITAL) study followed a cohort of over 36,000 peri- and postmenopausal females during six years of follow-up [<a href="#rid42">42</a>]. After adjusting for smoking and other confounding factors, the risk of incident lung cancer was increased for those who used an estrogen plus progestin. The risk was proportional to duration of hormone exposure (HR 1.48, 95% CI 1.03-2.12 for those with ≥10 years exposure to an estrogen plus progestin).</p><p></p><p>Endocrine factors also may have an impact on the natural history of disease if lung cancer does develop [<a href="#rid44">44</a>]. (See <a class="local">'Outcome'</a> below.)</p><p class="headingAnchor" id="H8"><span class="h2">Other risk factors</span><span class="headingEndMark"> — </span>Risk factors other than smoking that have been established for the development of lung cancer in males have also been confirmed for females. (See  <a class="medical medical_review" href="/z/d/html/4640.html" rel="external">"Cigarette smoking and other possible risk factors for lung cancer"</a>.) These include:</p><p class="bulletIndent1"><span class="glyph">●</span>A family history of lung cancer, which is both a risk factor on its own and has a significant interaction with smoking [<a href="#rid45">45,46</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A history of prior lung disease, which is a known risk factor in males and has been shown to be a risk factor in two case-control studies limited to females [<a href="#rid47">47,48</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An unresolved issue for both males and females is the relation between diet and vitamins and the development of lung cancer [<a href="#rid49">49-53</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h1">HISTOLOGY</span><span class="headingEndMark"> — </span>There is a consistent difference in the distribution of histologic types of lung cancer between males and females. Adenocarcinoma has replaced squamous cell carcinoma as the most common histologic type for both males and females, but proportionally more females than males are diagnosed with adenocarcinoma, and more males than females are diagnosed with squamous cell carcinoma [<a href="#rid11">11,21,22,54</a>].</p><p>A contemporary population-based case-control study of 4220 people in Italy demonstrated that among females diagnosed with lung cancer, the histologic sub-types were adenocarcinoma for 54 percent and squamous cell carcinoma for 11 percent compared with 38 and 30 percent, respectively, for males diagnosed with lung cancer [<a href="#rid22">22</a>]. Similar results were reported based on the United States National Surveillance, Epidemiology, and End Results (SEER) database. Histologic sub-types of lung cancer for 228,572 people diagnosed between 1975 and 1999 showed rates of adenocarcinoma and squamous cell carcinoma of 45 and 21 percent for females, compared with 33 and 36 percent for males [<a href="#rid11">11</a>].</p><p>Part of the explanation for differing distributions of lung cancer histology as well as different lung cancer biologies for males and females could be due to sex-related different susceptibilities to various molecular aberrations caused by smoking or other potential carcinogens [<a href="#rid21">21,55</a>]. There may also be differences in somatic gene mutations between the sexes. For example, epidermal growth factor receptor (<em>EGFR</em>) mutations are more prevalent in females and nonsmokers [<a href="#rid56">56,57</a>]. There do not appear to be differences in the prevalence of <em>KRAS</em> or <em>EML4-ALK</em> mutations between females and males [<a href="#rid55">55</a>]. It has been suggested, although not definitively demonstrated, that estrogen may influence histologic and molecular features of lung cancer and may explain some of the observed intersex differences in these characteristics [<a href="#rid57">57</a>].</p><p class="headingAnchor" id="H108737653"><span class="h1">OUTCOME</span><span class="headingEndMark"> — </span>Contemporary studies indicate that the prognosis of lung cancer in females is better than in males, at least for patients with adenocarcinoma [<a href="#rid58">58-61</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>An analysis from the United States Surveillance, Epidemiology, and End Results (SEER) and Medicare databases for 1991 to 1999 studied the outcomes in almost 19,000 patients over 65 years of age with stage I or II non-small cell lung cancer (NSCLC) [<a href="#rid58">58</a>]. Multivariate analysis revealed that both lung cancer-specific survival and overall survival were significantly better in females in all treatment groups (surgery with or without additional postoperative treatment, radiation therapy [RT] or chemotherapy without surgery, or untreated), with hazard ratios (HRs) of 0.72 to 0.78. Overall, these differences were reflected in a higher five-year survival rate in females (46 versus 38 percent in males).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A meta-analysis that included 2349 patients from five randomized trials evaluating contemporary, platinum-based chemotherapy regimens found that females had a longer overall survival than males (median 9.6 versus 8.6 months; HR 0.86, 95% CI 0.78-0.95) [<a href="#rid61">61</a>]. A significant difference was limited to patients with adenocarcinoma (median 10.9 versus 8.4 months; HR 0.70, 95% CI 0.59-0.83); the difference was not significant in patients with nonadenocarcinoma (survival 8.8 versus 8.5 months; HR 0.97, 95% CI 0.85-1.10).</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>A second meta-analysis that included 39 articles and 86,800 patients showed statistically significant improvement in overall survival with HRs for females versus males of 0.79 in studies using univariate analyses and 0.78 (p&lt;0.0001) in studies using multivariate analyses [<a href="#rid62">62</a>].</p><p></p><p>Endocrine factors may also affect the natural history of disease in females who develop NSCLC [<a href="#rid41">41,44</a>]. In the Women's Health Initiative trial, females on combined estrogen-progestin therapy had a significantly shorter survival compared with those given placebo (median survival 9.4 versus 16.1 months, HR 1.59) [<a href="#rid40">40,41</a>]. These findings are consistent with the hypothesis that endocrine factors either accelerate the transition of a preneoplastic lesion to an overt malignancy or promote tumor growth once a malignancy is evident.</p><p>Although these data require confirmation, discontinuation of postmenopausal hormone therapy should be considered in females diagnosed with lung cancer [<a href="#rid63">63</a>].</p><p>Sex-related differences in lung cancer gene mutations (eg, <em>EGFR</em> mutations) may also explain some of the treatment outcome disparities between females and males [<a href="#rid55">55</a>]. Female sex is a significant clinical prognostic factor for patients treated with EGFR tyrosine kinase inhibitors.</p><p class="headingAnchor" id="H11"><span class="h1">TREATMENT</span><span class="headingEndMark"> — </span>Solving the problem of lung cancer in females has three major components: prevention, early detection, and improved methods of treatment.</p><p class="headingAnchor" id="H12"><span class="h2">Prevention</span><span class="headingEndMark"> — </span>The most effective intervention will be to stop people from smoking altogether, since approximately 85 to 90 percent of lung cancer cases are attributable to smoking [<a href="#rid64">64</a>]. Smoking prevalence rates for males and females in the United States have decreased since their peaks in the 1960s. Smoking rates for United States females were 34 percent in 1965 and 21 percent in 2000 [<a href="#rid65">65</a>]. Smoking prevalence in the United States in 2011 was about 19 percent [<a href="#rid17">17</a>]. Convincing individuals to stop smoking, however, is not an easy task. Smoking rates remain unacceptably high despite the overwhelming evidence that smoking causes lung cancer as well as other fatal health problems. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p>The prevalence of smoking is disproportionately high among young girls and the less educated. In 2000, 30 percent of high school girls were smokers, and a report from 2001 described that smoking rates for females with less than a high school education were three times higher than for females with a college education [<a href="#rid66">66,67</a>].</p><p>The study of other methods of lung cancer prevention, including the role of diet and vitamins, should also be pursued. (See  <a class="medical medical_review" href="/z/d/html/4604.html" rel="external">"Chemoprevention of lung cancer"</a>.)</p><p class="headingAnchor" id="H13"><span class="h2">Early detection</span><span class="headingEndMark"> — </span>The data from clinical trials examining screening and the delineation of specific populations for whom this approach is beneficial are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/7566.html" rel="external">"Screening for lung cancer"</a>.)</p><p class="headingAnchor" id="H14"><span class="h2">Improvements in treatment</span><span class="headingEndMark"> — </span>Substantial gains are being made in the treatment of lung cancer, particularly with respect to understanding the underlying pathogenesis and personalizing cancer care on that basis. (See  <a class="medical medical_review" href="/z/d/html/4607.html" rel="external">"Overview of the initial treatment of advanced non-small cell lung cancer"</a> and  <a class="medical medical_review" href="/z/d/html/16538.html" rel="external">"Personalized, genotype-directed therapy for advanced non-small cell lung cancer"</a>.)</p><p>Preclinical and clinical trials should continue to be supported, and sex should be addressed as a specific research variable. Females should be actively recruited for enrollment in lung cancer clinical trials [<a href="#rid15">15,49,68</a>].</p><p class="headingAnchor" id="H1868869326"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112231.html" rel="external">"Society guideline links: Diagnosis and management of lung cancer"</a>.)</p><p class="headingAnchor" id="H15"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Epidemiology</strong> – Although the incidence of lung cancer in females (and males) continues to decrease, it remains the leading cancer killer in females as well as males. The vast majority of lung cancer cases are attributable to smoking, and smoking prevalence rates in females are still unacceptably high. (See <a class="local">'Epidemiology'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factors</strong> – It is unresolved whether etiologic factors contributing to lung cancer differ in females and males, but there do appear to be some distinctions. The magnitude of the effect of smoking on the risk of developing the disease may not be different across the sexes, but smoking appears to have an impact on the histology of lung cancer.</p><p></p><p class="bulletIndent1">Finally, although the evidence is not entirely clear, endocrine factors may influence both the development of lung cancer and its subsequent natural history. Consideration should be given to discontinuing postmenopausal hormone therapy in females diagnosed with lung cancer.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin 2023; 73:17.</a></li><li><a class="nounderline abstract_t">Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95:1276.</a></li><li><a class="nounderline abstract_t">Gasperino J, Rom WN. Gender and lung cancer. Clin Lung Cancer 2004; 5:353.</a></li><li><a class="nounderline abstract_t">Thomas L, Doyle LA, Edelman MJ. Lung cancer in women: emerging differences in epidemiology, biology, and therapy. Chest 2005; 128:370.</a></li><li><a class="nounderline abstract_t">Pauk N, Kubík A, Zatloukal P, Krepela E. Lung cancer in women. Lung Cancer 2005; 48:1.</a></li><li><a class="nounderline abstract_t">Jemal A, Simard EP, Dorell C, et al. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels. J Natl Cancer Inst 2013; 105:175.</a></li><li><a class="nounderline abstract_t">Didkowska J, Manczuk M, McNeill A, et al. Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics. BMJ 2005; 331:189.</a></li><li><a class="nounderline abstract_t">Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 2021; 71:209.</a></li><li><a class="nounderline abstract_t">Shibuya K, Inoue M, Lopez AD. Statistical modeling and projections of lung cancer mortality in 4 industrialized countries. Int J Cancer 2005; 117:476.</a></li><li><a class="nounderline abstract_t">Edwards BK, Brown ML, Wingo PA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005; 97:1407.</a></li><li><a class="nounderline abstract_t">Fu JB, Kau TY, Severson RK, Kalemkerian GP. Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database. Chest 2005; 127:768.</a></li><li><a class="nounderline abstract_t">Jemal A, Miller KD, Ma J, et al. Higher Lung Cancer Incidence in Young Women Than Young Men in the United States. N Engl J Med 2018; 378:1999.</a></li><li><a class="nounderline abstract_t">Wakelee HA, Chang ET, Gomez SL, et al. Lung cancer incidence in never smokers. J Clin Oncol 2007; 25:472.</a></li><li><a class="nounderline abstract_t">Thun MJ, Carter BD, Feskanich D, et al. 50-year trends in smoking-related mortality in the United States. N Engl J Med 2013; 368:351.</a></li><li><a class="nounderline abstract_t">Wingo PA, Ries LA, Giovino GA, et al. Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking. J Natl Cancer Inst 1999; 91:675.</a></li><li class="breakAll">Office of the Surgeon General. The Health Consequences of Smoking: A Report of the Surgeon General. US Department of Health and Human Services; Washington, DC, 2004. CDC Publication No. 7829.</li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Current cigarette smoking among adults - United States, 2011. MMWR Morb Mortal Wkly Rep 2012; 61:889.</a></li><li><a class="nounderline abstract_t">Zang EA, Wynder EL. Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers. Cancer 1992; 70:69.</a></li><li><a class="nounderline abstract_t">Osann KE, Anton-Culver H, Kurosaki T, Taylor T. Sex differences in lung-cancer risk associated with cigarette smoking. Int J Cancer 1993; 54:44.</a></li><li><a class="nounderline abstract_t">Taubes G. Claim of higher risk for women smokers attacked. Science 1993; 262:1375.</a></li><li><a class="nounderline abstract_t">Patel JD, Bach PB, Kris MG. Lung cancer in US women: a contemporary epidemic. JAMA 2004; 291:1763.</a></li><li><a class="nounderline abstract_t">De Matteis S, Consonni D, Pesatori AC, et al. Are women who smoke at higher risk for lung cancer than men who smoke? Am J Epidemiol 2013; 177:601.</a></li><li><a class="nounderline abstract_t">Wang A, Kubo J, Luo J, et al. Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort. Ann Oncol 2015; 26:221.</a></li><li><a class="nounderline abstract_t">Schoenberg JB, Wilcox HB, Mason TJ, et al. Variation in smoking-related lung cancer risk among New Jersey women. Am J Epidemiol 1989; 130:688.</a></li><li><a class="nounderline abstract_t">Risch HA, Howe GR, Jain M, et al. Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type. Am J Epidemiol 1993; 138:281.</a></li><li><a class="nounderline abstract_t">Harris RE, Zang EA, Anderson JI, Wynder EL. Race and sex differences in lung cancer risk associated with cigarette smoking. Int J Epidemiol 1993; 22:592.</a></li><li><a class="nounderline abstract_t">Bain C, Feskanich D, Speizer FE, et al. Lung cancer rates in men and women with comparable histories of smoking. J Natl Cancer Inst 2004; 96:826.</a></li><li><a class="nounderline abstract_t">Prescott E, Osler M, Hein HO, et al. Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies. Epidemiology 1998; 9:79.</a></li><li><a class="nounderline abstract_t">Hansen MS, Licaj I, Braaten T, et al. Sex Differences in Risk of Smoking-Associated Lung Cancer: Results From a Cohort of 600,000 Norwegians. Am J Epidemiol 2018; 187:971.</a></li><li class="breakAll">Chollat-Traquet C. Women and Tobacco, World Health Organization, Geneva 1992.</li><li><a class="nounderline abstract_t">Ezzati M, Lopez AD. Estimates of global mortality attributable to smoking in 2000. Lancet 2003; 362:847.</a></li><li><a class="nounderline abstract_t">Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011; 61:69.</a></li><li><a class="nounderline abstract_t">Preston DL, Ron E, Tokuoka S, et al. Solid cancer incidence in atomic bomb survivors: 1958-1998. Radiat Res 2007; 168:1.</a></li><li><a class="nounderline abstract_t">Tucker MA, Coleman CN, Cox RS, et al. Risk of second cancers after treatment for Hodgkin's disease. N Engl J Med 1988; 318:76.</a></li><li><a class="nounderline abstract_t">van Leeuwen FE, Klokman WJ, Stovall M, et al. Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease. J Natl Cancer Inst 1995; 87:1530.</a></li><li><a class="nounderline abstract_t">Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 2002; 94:182.</a></li><li><a class="nounderline abstract_t">Kaufman EL, Jacobson JS, Hershman DL, et al. Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008; 26:392.</a></li><li><a class="nounderline abstract_t">Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003; 56:83.</a></li><li><a class="nounderline abstract_t">Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys 2006; 65:1.</a></li><li><a class="nounderline abstract_t">Heiss G, Wallace R, Anderson GL, et al. Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin. JAMA 2008; 299:1036.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Schwartz AG, Wakelee H, et al. Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet 2009; 374:1243.</a></li><li><a class="nounderline abstract_t">Slatore CG, Chien JW, Au DH, et al. Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study. J Clin Oncol 2010; 28:1540.</a></li><li><a class="nounderline abstract_t">Chlebowski RT, Anderson GL, Manson JE, et al. Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial. J Natl Cancer Inst 2010; 102:1413.</a></li><li><a class="nounderline abstract_t">Ganti AK, Sahmoun AE, Panwalkar AW, et al. Hormone replacement therapy is associated with decreased survival in women with lung cancer. J Clin Oncol 2006; 24:59.</a></li><li><a class="nounderline abstract_t">Osann KE. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res 1991; 51:4893.</a></li><li><a class="nounderline abstract_t">Horwitz RI, Smaldone LF, Viscoli CM. An ecogenetic hypothesis for lung cancer in women. Arch Intern Med 1988; 148:2609.</a></li><li><a class="nounderline abstract_t">Wu AH, Fontham ET, Reynolds P, et al. Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States. Am J Epidemiol 1995; 141:1023.</a></li><li><a class="nounderline abstract_t">Alavanja MC, Brownson RC, Boice JD Jr, Hock E. Preexisting lung disease and lung cancer among nonsmoking women. Am J Epidemiol 1992; 136:623.</a></li><li><a class="nounderline abstract_t">Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group. The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994; 330:1029.</a></li><li><a class="nounderline abstract_t">Menkes MS, Comstock GW, Vuilleumier JP, et al. Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer. N Engl J Med 1986; 315:1250.</a></li><li><a class="nounderline abstract_t">Steinmetz KA, Potter JD, Folsom AR. Vegetables, fruit, and lung cancer in the Iowa Women's Health Study. Cancer Res 1993; 53:536.</a></li><li><a class="nounderline abstract_t">Wu AH, Henderson BE, Pike MC, Yu MC. Smoking and other risk factors for lung cancer in women. J Natl Cancer Inst 1985; 74:747.</a></li><li><a class="nounderline abstract_t">Tanvetyanon T, Bepler G. Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands. Cancer 2008; 113:150.</a></li><li><a class="nounderline abstract_t">Pinsky PF, Church TR, Izmirlian G, Kramer BS. The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology. Cancer 2013; 119:3976.</a></li><li><a class="nounderline abstract_t">North CM, Christiani DC. Women and lung cancer: what is new? Semin Thorac Cardiovasc Surg 2013; 25:87.</a></li><li><a class="nounderline abstract_t">Hsieh RK, Lim KH, Kuo HT, et al. Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer. Chest 2005; 128:317.</a></li><li><a class="nounderline abstract_t">Yang SY, Yang TY, Chen KC, et al. EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients. Clin Cancer Res 2011; 17:2149.</a></li><li><a class="nounderline abstract_t">Wisnivesky JP, Halm EA. Sex differences in lung cancer survival: do tumors behave differently in elderly women? J Clin Oncol 2007; 25:1705.</a></li><li><a class="nounderline abstract_t">Cerfolio RJ, Bryant AS, Scott E, et al. Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men. Chest 2006; 130:1796.</a></li><li><a class="nounderline abstract_t">Chansky K, Sculier JP, Crowley JJ, et al. The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer. J Thorac Oncol 2009; 4:792.</a></li><li><a class="nounderline abstract_t">Wheatley-Price P, Blackhall F, Lee SM, et al. The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials. Ann Oncol 2010; 21:2023.</a></li><li><a class="nounderline abstract_t">Nakamura H, Ando K, Shinmyo T, et al. Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis. Ann Thorac Cardiovasc Surg 2011; 17:469.</a></li><li><a class="nounderline abstract_t">Siegfried JM. Hormone replacement therapy and decreased lung cancer survival. J Clin Oncol 2006; 24:9.</a></li><li><a class="nounderline abstract_t">Alberg AJ, Samet JM. Epidemiology of lung cancer. Chest 2003; 123:21S.</a></li><li><a class="nounderline abstract_t">Giovino GA. Epidemiology of tobacco use in the United States. Oncogene 2002; 21:7326.</a></li><li class="breakAll">Johnston LD, Bachman JG, O'Malley PM. Monitoring the Future: Questionnaire Responses From the Nation’s High School Seniors, Ann Arbor: Institute for Social Research, University of Michigan, 2001.</li><li class="breakAll">Office of the Surgeon General. Women and Smoking: A Report of the Surgeon General. US Dept Health and Human Services, Public Health Service; Washington, DC, 2001.</li><li><a class="nounderline abstract_t">Lung Cancer Study Group. Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung. N Engl J Med 1986; 315:1377.</a></li></ol></div><div id="topicVersionRevision">Topic 1431 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36633525" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Cancer statistics, 2023.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12953083" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Annual report to the nation on the status of cancer, 1975-2000, featuring the uses of surveillance data for cancer prevention and control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15217534" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Gender and lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002959" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Lung cancer in women: emerging differences in epidemiology, biology, and therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15777966" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Lung cancer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23297039" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16037450" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Lung cancer mortality at ages 35-54 in the European Union: ecological study of evolving tobacco epidemics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33538338" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15906356" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Statistical modeling and projections of lung cancer mortality in 4 industrialized countries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16204691" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15764756" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Lung cancer in women: analysis of the national Surveillance, Epidemiology, and End Results database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29791813" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Higher Lung Cancer Incidence in Young Women Than Young Men in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17290054" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Lung cancer incidence in never smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23343064" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 50-year trends in smoking-related mortality in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10218505" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Annual report to the nation on the status of cancer, 1973-1996, with a special section on lung cancer and tobacco smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23134971" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Current cigarette smoking among adults - United States, 2011.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1606549" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Cumulative tar exposure. A new index for estimating lung cancer risk among cigarette smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8386708" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Sex differences in lung-cancer risk associated with cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8248778" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Claim of higher risk for women smokers attacked.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15082704" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Lung cancer in US women: a contemporary epidemic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23425629" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Are women who smoke at higher risk for lung cancer than men who smoke?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25316260" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Active and passive smoking in relation to lung cancer incidence in the Women's Health Initiative Observational Study prospective cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2549787" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Variation in smoking-related lung cancer risk among New Jersey women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8395141" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Are female smokers at higher risk for lung cancer than male smokers? A case-control analysis by histologic type.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8225730" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Race and sex differences in lung cancer risk associated with cigarette smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15173266" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Lung cancer rates in men and women with comparable histories of smoking.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9430273" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Gender and smoking-related risk of lung cancer. The Copenhagen Center for Prospective Population Studies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29087432" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Sex Differences in Risk of Smoking-Associated Lung Cancer: Results From a Cohort of 600,000 Norwegians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29087432" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Sex Differences in Risk of Smoking-Associated Lung Cancer: Results From a Cohort of 600,000 Norwegians.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/13678970" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Estimates of global mortality attributable to smoking in 2000.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21296855" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Global cancer statistics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17722996" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Solid cancer incidence in atomic bomb survivors: 1958-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3336397" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Risk of second cancers after treatment for Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7563187" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Roles of radiotherapy and smoking in lung cancer following Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11830608" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18202415" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12694826" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Radiation-induced second cancers: the impact of 3D-CRT and IMRT.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16618572" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Intensity-modulated radiation therapy, protons, and the risk of second cancers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18319414" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Health risks and benefits 3 years after stopping randomized treatment with estrogen and progestin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19767090" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20159813" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Lung cancer and hormone replacement therapy: association in the vitamins and lifestyle study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20709992" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Lung cancer among postmenopausal women treated with estrogen alone in the women's health initiative randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314616" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Hormone replacement therapy is associated with decreased survival in women with lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1654203" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2848471" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : An ecogenetic hypothesis for lung cancer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7771438" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Previous lung disease and risk of lung cancer among lifetime nonsmoking women in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442729" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Preexisting lung disease and lung cancer among nonsmoking women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8127329" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3773937" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Serum beta-carotene, vitamins A and E, selenium, and the risk of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8425185" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Vegetables, fruit, and lung cancer in the Iowa Women's Health Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3857370" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Smoking and other risk factors for lung cancer in women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18429004" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Beta-carotene in multivitamins and the possible risk of lung cancer among smokers versus former smokers: a meta-analysis and evaluation of national brands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24037918" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : The National Lung Screening Trial: results stratified by demographics, smoking history, and lung cancer histology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24216523" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Women and lung cancer: what is new?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16002952" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Female sex and bronchioloalveolar pathologic subtype predict EGFR mutations in non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21300759" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : EGFR L858R mutation and polymorphisms of genes related to estrogen biosynthesis and metabolism in never-smoking female lung adenocarcinoma patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17470862" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Sex differences in lung cancer survival: do tumors behave differently in elderly women?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17166999" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Women with pathologic stage I, II, and III non-small cell lung cancer have better survival than men.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19458556" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : The International Association for the Study of Lung Cancer Staging Project: prognostic factors and pathologic TNM stage in surgically managed non-small cell lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20332134" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : The influence of sex and histology on outcomes in non-small-cell lung cancer: a pooled analysis of five randomized trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21881356" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Female gender is an independent prognostic factor in non-small-cell lung cancer: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16314612" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Hormone replacement therapy and decreased lung cancer survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12527563" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Epidemiology of lung cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12379876" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Epidemiology of tobacco use in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12379876" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Epidemiology of tobacco use in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12379876" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Epidemiology of tobacco use in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2877397" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Effects of postoperative mediastinal radiation on completely resected stage II and stage III epidermoid cancer of the lung.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
